HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China.

摘要: Patients with antiretroviral therapy interruption have a high risk of virological failure when re-initiating (ART), especially those HIV drug resistance. Next-generation sequencing may provide close scrutiny on their minority resistance variant. A cross-sectional study was conducted in patients ART five regions China 2016. Through Sanger and next-generation parallel, genotyped plasma samples. Rates were compared by the McNemar tests. In total, 174 included this study, median 12 (interquartile range (IQR), 6–24) months interruption. Most (86.2%) them had received efavirenz (EFV)/nevirapine (NVP)-based first-line for 16 (IQR, 7–26) before Sixty-one (35.1%) CRF07_BC HIV-1 strains, 58 (33.3%) CRF08_BC 35 (20.1%) CRF01_AE. Thirty-four (19.5%) detected to harbor drug-resistant variants sequencing. Thirty-six (20.7%), 37 (21.3%), 42 (24.1%), 79 (45.4%) 139 (79.9) identified at 20% (v.s. Sanger, p = 0.317), 10% 0.180), 5% 0.011), 2% frequency such as K103N, M184VI P225H still existed, but decreased frequencies. The prevalence higher than 15% survey. able detect more Sanger. There sharp increase detection threshold below 5%.